|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for PROM1(NM_006017.2) Search again
Product ID:
HQP115120
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
AC133, CD133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4
Gene Description:
prominin 1
Target Gene Accession:
NM_006017.2(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes a pentaspan transmembrane glycoprotein.
Gene References into function
- A new locus was identified for a bull's-eye macular dystrophy on the short arm of chromosome 4.
- transcription of AC133 isoforms is controlled by 5 alternative promoters, and in vitro methylation of 2 of these AC133 promoters completely suppresses their activity, suggesting that methylation plays a role in their regulation
- immediately after separation, 96.75+/-0.58% of CD133+ cells and 97.04+/-1.76% of CD133- cells were in G0/G1-phase
- a small population (approximately 1%) of human prostate basal cells express the cell surface marker CD133
- redistribute several lipid raft markers including cholesterol-binding protein prominin-1 (CD133) in specialized plasma membrane domains
- Data report that a subpopulation of circulating cells expressing AC133 can restore dystrophin expression and ameliorate function in dystrophic skeletal muscle.
- In adults, the expression of human prominin-1 is not limited to stem and progenitor cells, and the epitopes of prominin-1 might be useful for investigating solid cancers.
- New cd133+ cell subpopulation, which is apparently a precursor classical endothelial progenitor cells more potent with respect too homing and vasscular repair.
- CD133 mRNA expression is increased in cancer patients with metastatic disease, specifically with bone metastasis. In addition, CD133 mRNA expression seems to be an independent prognostic factor for overall survival.
- sialomucin endolyn (CD164), an adhesion receptor that regulates the adhesion of CD34+ cells to bone marrow stroma and the recruitment of CD34+CD38(lo/-) cells into cycle, associates with CXCR4
- CD133-posistive and CD133-negative glioma cells may be similarly resistant to immune surveillance, but INF-gamma may partially restore their immunogenicity and potentiate their lysis by NK cells.
- colon cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells
- CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
- The differences between the gene expression profiles of CD34(+) and CD133(+) cells indicate the more primitive nature of CD133(+) cells suggesting that CD34(+) and CD133(+) cells may have different roles in hematopoietic regeneration.
- Comparative genomics on PROM1 gene encoding stem cell marker CD133.
- Elevated circulating endothelial progenitor marker CD133 messenger RNA levels are associated with colon cancer recurrence
- phenotypic characteristics of retinopathy caused by nonsense mutations in PROM1
- Novel germ cell markers PROM1 were significantly upregulated in seminoma specimens, compared to normal testes.
- CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
- Tissue factor expression contributes to tumor growth/regulating properties of CD133-positive tumor stem cells.
- Here we tested the safety of autologous transplantation of muscle-derived CD133+ cells in eight boys with Duchenne muscular dystrophy in a 7-month, double-blind phase I clinical trial.
- Data show that a reduction in the oxygen level in these cell cultures dramatically increases the percentage of CD133 expressing cells.
- The neurotransmitter GABA is a potent blocker of the SDF-1alpha-induced migration of CD133(+) hematopoietic stem and progenitor cells from mobilized peripheral blood.
- Human cerebrospinal fluid contains specific membrane particles that carry prominin-1/CD133, a neural stem cell marker implicated in brain tumors, notably glioblastoma.
- CD133 stem cell antigen expression correlates with patient survival in gliomas.
- data show that pancreatic duct cells express prominin-1 and surprisingly reveal that its particular AC133 epitope is not an exclusive stem and progenitor cell marker
- cancer stem cells and expression of CD133 is predictive of prognosis in high-grade oligodendroglial tumors.
- CD133 molecule represents another cell surface marker suitable for identification and isolation of pancreatic endocrine progenitors.
- analysis of CD133-expression and neuronal lineage differentiation potential in high-grade glioma
- Study provides a unique genome-wide molecular signature of CD133+ and CD133- human prostate epithelial cells.
- CD133 which might be correlated with the development and progression of neuroblastoma can serve as one of the important indicators for prognosis of neuroblastoma.
- Relevant animal models can reliably preserve CD133(+) tumor cell pools even during serial in vivo subtransplantations.
- CD133 has roles in metastatic colon cancer and is expressed in colon cancer stem cells
- CD133 associates with the endosomal compartment of mitotic hHSCs
- hepatocellular, pancreatic and gastric cancer cell lines expressed CD133 at levels higher than normal epithelial cells or bone marrow progenitor cells.
- Report a correlation between expression of CD133 and drug resistance in glioblastomas.
- The methylation of promoter P2 was tissue specific, and hypomethylation of this promoter is probably necessary but not sufficient for efficient transcription of the PROM1 gene.
- ALDH, expressed along CD133, can more specifically characterize the tumorigenic liver cancer stem cells population.
- Overall expression of human prominin-1 is beyond the rare primitive cells, and it seems to be a general marker of apical or apicolateral membrane of glandular epithelia.
- Mutant PROM1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.
- DNA hypomethylation is an important determinant of CD133 expression in glioblastomas, and this epigenetic event may be associated with the development of Brain tumor-initiating cells expressing CD133.
- diagnostic value of clone AC141 of CD133 antibody by flow cytometry in acute leukemia
- CD133 overexpression is a risk factor for poorer overall survival in patients with well- and moderately-differentiated adenocarcinoma
- CD133 expression in colorectal cancer is an independent prognostic marker
- The association of AC133 with actively cycling cells may contribute to the basis for enrichment for tumor-initiating activity.
- The CD133 DNA methylation seems to constitute an abnormal promoter signature because it is not found in normal brain and colon but only in cultured and primary tumors.
- The concept that CD133 is a marker of brain tumor stem cells may need to be revised.
- Unlike normal adult prostate stem cells, prostate cancer initiating cells are AR+ and do not require functional CD133.
- Results identify a subpopulation of CD133(+) cells expressing the B-cell marker CD20, which display myogenic properties.